Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TTK | P33981 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941507 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL29693577 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL8866586 | 0.85 | TTK (0.73) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL7817760 | 0.84 | PIM1 (0.72) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL7810309 | 0.84 | TTK (0.72) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL8796454 | 0.81 | TTK (0.67) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL8796647 | 0.80 | MEN1 (0.67) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL9201258 | 0.80 | MEN1 (0.67) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL13280525 | 0.79 | MAPT (0.66) | ALDH1A1KMT2ATTKNPC1MAPT | |
| SCHEMBL7946079 | 0.79 | KDR (0.65) | ALDH1A1KMT2ATTKNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203516-A1 | SYSTEMS AND METHODS FOR CELLULAR REPROGRAMMING OF A PLANT CELL | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-06-29 | — | — | US | claimed |
| CN-116218033-A | Application of organic material in preparing color-changeable polymer material | 四川大学 | 2023-06-06 | — | — | CN | claimed |
| US-11447786-B2 | Systems and methods for cellular reprogramming of a plant cell | PIONEER HI-BRED INTERNATIONAL, INC. | 2022-09-20 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-20210100803-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | THE UNIVERSITY OF CHICAGO | 2021-04-08 | — | — | US | claimed |
| US-10675331-B2 | Method for achieving desired glial growth factor 2 plasma levels | ACORDA THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-20070003531-A1 | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes | UNIVERSITY OF CONNECTICUT | 2007-01-04 | — | — | US | claimed |
| US-7026296-B2 | Methods of treating dry eye disorders | ALCON, INC. (CH) | 2006-04-11 | — | — | US | claimed |
| EP-1542768-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | Alcon, Inc. (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026406-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | ALCON, INC. (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20040058875-A1 | Methods of treating dry eye disorders | ALCON, INC. | 2004-03-25 | — | — | US | claimed |
| EP-0244819-B1 | Improved process for preparing substituted anthra[1,9-cd]-pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0203697-B1 | A process for preparing substituted anthra[1,9-od]pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1990-06-13 | — | — | EP | claimed |
| US-4672129-A | Process for preparing substituted anthra[1,9-cd]pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1987-06-09 | — | — | US | claimed |
| EP-0203697-A1 | A process for preparing substituted anthra[1,9-od]pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1986-12-03 | — | — | EP | claimed |
| US-4608439-A | Process for preparing substituted anthra[1,9-cd]pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1986-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003531-A1 | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes | AIFM1, APAF1, CASP6 | ALDH1A1 2038/4885KMT2A 1990/4885TTK 1239/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | ALDH1A1 3269/4885KMT2A 4104/4885TTK 2312/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | ALDH1A1 4773/4885KMT2A 3992/4885TTK 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.